Results 11 to 20 of about 160,542 (279)

Pembrolizumab alone and pembrolizumab plus chemotherapy in previously treated, extrapulmonary poorly differentiated neuroendocrine carcinomas [PDF]

, 2023
BackgroundTo date, single-agent immune checkpoint inhibitor (CPI) therapy has proven to be ineffective against biomarker-unselected extrapulmonary poorly differentiated neuroendocrine carcinomas (EP-PDNECs).
Kimberly Perez, Wang, Stephanie J, Chan, Jennifer A, Mulvey, Claire K, Pamela N. Munster, Emily K. Bergsland, Fong, Lawrence, Hope, Thomas A, Susan Calabrese, Grabowsky, Jennifer, Rahul R. Aggarwal, Diane Reidy-Lagunes, Li Zhang, Stephanie J. Wang, Perez, Kimberly, DeMore, April, Reidy-Lagunes, Diane, Claire K. Mulvey, Sippy Punn, Sofia Von Fedak, April DeMore, Kolli, Kanti Pallav, Bergsland, Emily K, Lawrence Fong, Von Fedak, Sofia, Zhang, Li, Raj, Nitya, Jennifer A. Chan, Jennifer Grabowsky, Thomas A. Hope, Punn, Sippy, Kanti Pallav Kolli, Aggarwal, Rahul R, Nitya Raj, Calabrese, Susan, Munster, Pamela N   +35 more
core   +1 more source

Two‐year efficacy of SNK01 plus pembrolizumab for non‐small cell lung cancer: Expanded observations from a phase I/IIa randomized controlled trial

Thoracic Cancer, 2022
Background A previous trial showed that autologous ex‐vivo expanded NK cell (SNK01) treatment combined with pembrolizumab showed better efficacy than pembrolizumab monotherapy in advanced non‐small cell lung cancer (NSCLC). This study was a 2‐year follow‐
Hyung Jun Park, Yong Man Kim, Jae Seob Jung, Wonjun Ji, Jae Cheol Lee, Chang‐Min Choi   +5 more
doaj   +1 more source

Discontinuation of pembrolizumab for advanced urothelial carcinoma without disease progression: Nationwide cohort study

Cancer Medicine, 2023
Pembrolizumab, an anti‐programmed death 1 monoclonal antibody, has revolutionized the treatment of metastatic urothelial carcinoma. However, the optimal treatment duration for treatment responders has not been established.
Katsuhiro Ito, Yuki Kita, Akira Yokomizo, Jun Miki, Yuko Yoshio, Hiroaki Matsumoto, Takehiko Segawa, Takashi Karashima, Naotaka Nishiyama, Kazuto Imai, Shigetaka Suekane, Seiji Nagasawa, Shin Higashi, Hiroyuki Nishiyama, Hiroshi Kitamura, Takashi Kobayashi   +15 more
doaj   +1 more source

A Case of Stevens-Johnson Syndrome/toxic epidermal necrolysis in a patient receiving chemo-immunotherapy with pemetrexed and pembrolizumab

Current Problems in Cancer: Case Reports, 2021
Chemo-immunotherapy consisting of pemetrexed and pembrolizumab is first line therapy for individuals with non-squamous non-small cell lung cancer without ALK or EGFR mutations.
Michael H. Storandt, Rishi Seth
doaj   +1 more source

First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy

Journal for ImmunoTherapy of Cancer, 2019
Pembrolizumab monotherapy has become the preferred treatment for patients with advanced non-small cell lung carcinoma (NSCLC) and a programmed cell death-ligand 1 (PD-L1) tumor proportion score (TPS) of at least 50%.
Zuan Lin
doaj   +1 more source

Unilateral Pneumonitis and Hydropneumothorax Following Pembrolizumab [PDF]

, 2022
A man in his 80s with metastatic melanoma presented with progressive dyspnea on exertion and dry cough after 7 cycles of pembrolizumab monotherapy. He was initially treated with antibiotics for community acquired pneumonia; however, his symptoms recurred
Christine Minerowicz, Andrew Sanchez, Harriet Kluger, Peter Kahn   +3 more
core  

Pembrolizumab induced-C3 glomerulonephritis and RBC cast nephropathy: a case report

BMC Nephrology, 2023
Background Immune checkpoint inhibitors (ICIs) are increasingly being used in the treatment of several cancers. Pembrolizumab is an anti-programmed cell death-1 (anti-PD-1) monoclonal antibody that is approved for the treatment of metastatic non-small ...
Zhi Yang, Huan Xu, Shenju Gou, Hongyan Wu, Zhangxue Hu   +4 more
doaj   +1 more source

Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: Longer-Term Follow-Up From the Phase 3 KEYNOTE-240 Trial

Liver Cancer, 2023
Introduction: KEYNOTE-240 showed a favorable benefit/risk profile for pembrolizumab versus placebo in patients with sorafenib-treated advanced hepatocellular carcinoma (HCC); however, prespecified statistical significance criteria for overall survival ...
Philippe Merle, Masatoshi Kudo, Julien Edeline, Mohamed Bouattour, Ann-Lii Cheng, Stephen Lam Chan, Thomas Yau, Marcelo Garrido, Jennifer Knox, Bruno Daniele, Valeriy Breder, Ho Yeong Lim, Sadahisa Ogasawara, Stéphane Cattan, Yee Chao, Abby B. Siegel, Iván Martinez-Forero, Ziwen Wei, Chih-Chin Liu, Richard S. Finn   +19 more
doaj   +1 more source

Intralymphatic histiocytosis in a patient with lung adenocarcinoma treated with pembrolizumab: a case report

Journal for ImmunoTherapy of Cancer, 2019
Background Pembrolizumab, an anti-programmed cell death-1 protein monoclonal antibody, is effective for patients with advanced non-small-cell lung cancer.
Teppei Sugano, Masahiro Seike, Yoko Funasaka, Mai Yoshida, Ryoko Takayama, Ken Okamura, Asuka Nakanishi, Toru Tanaka, Susumu Takeuchi, Rintaro Noro, Yuji Minegishi, Kaoru Kubota, Hidehisa Saeki, Akihiko Gemma   +13 more
doaj   +1 more source

Real-world treatment patterns and outcomes among individuals receiving first-line pembrolizumab therapy for recurrent/metastatic head and neck squamous cell carcinoma

Frontiers in Oncology, 2023
BackgroundPembrolizumab, a PD-1 immune checkpoint inhibitor, is approved as first-line (1L) treatment for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) as monotherapy or in combination with platinum and 5-fluorouracil ...
Christopher M. Black, Glenn J. Hanna, Liya Wang, Karthik Ramakrishnan, Daisuke Goto, Vladimir Turzhitsky, Gleicy M. Hair   +6 more
doaj   +1 more source